Skip to Content
Merck
  • Differential expression of MART-1 in primary and metastatic melanoma lesions.

Differential expression of MART-1 in primary and metastatic melanoma lesions.

Journal of immunotherapy (Hagerstown, Md. : 1997) (1997-12-31)
T Kageshita, Y Kawakami, S Hirai, T Ono
ABSTRACT

Twenty-eight primary and 29 metastatic melanoma lesions and 18 pigmented nevi lesions were analyzed by using the immunoperoxidase reaction with anti-MART-1 and anti-gp100 monoclonal antibodies (mAbs). The MART-1 was expressed in 28, 29, and 18, and gp100 was expressed in 27, 28, and eight of these lesions, respectively. Intensity and percentage of stained cells with anti-MART-1 mAb were stronger and higher than those with anti-gp100 mAb. MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. The level of expression of MART-1 in primary melanoma lesions did not correlate with any clinicopathologic parameters. These results suggest that anti-MART-1 mAb is a useful tool for immunohistochemical analysis of melanocytic lesions and also is useful for patients' selection and monitoring of antigen-loss variants in clinical trials with the MART-1-based immunotherapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MART-1 (Melan A) (M2-7C10) Mouse Monoclonal Antibody
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
MART-1 (Melan A) (A103) Mouse Monoclonal Antibody
SKU
Pack Size
Availability
Price
Quantity